SEC Form 4 · accession 0001209191-18-019565

TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Growth Markets Commercial

Period of report

Mar 12, 2018

Accepted (ET)

Mar 14, 2018 · 4:31 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000818686

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F1,F2	Mar 12, 2018	M	880	—	A	5,792	D
Ordinary Shares^F1,F4	Mar 12, 2018	S	461	$19.498	D	5,331	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F2,F5,F1	—	Mar 12, 2018	M	880	D	—	—	Ordinary Shares	880	883	D

F1The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.49 to $19.5107, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5Restricted share units were granted on March 12, 2015, with 880 vesting on March 12, 2018 and 883 vesting on March 12, 2019.